cinnarizine and Motion-Sickness

Motion sickness is a syndrome that occurs as a result of passive body movement in response to actual motion, or the illusion of motion when exposed to virtual and moving visual environments. The most common symptoms are nausea and vomiting. Antihistamines have been used in the management of motion sickness for decades, however studies have shown conflicting results regarding their efficacy.. To assess the effectiveness of antihistamines in the prevention and treatment of motion sickness in adults and children.. The Cochrane ENT Information Specialist searched the Cochrane ENT Register; Central Register of Controlled Trials; Ovid MEDLINE; Ovid Embase; Web of Science; ClinicalTrials.gov; ICTRP and additional sources for published and unpublished trials. The date of the search was 7 December 2021.. Randomised controlled trials (RCTs) in susceptible adults and children in whom motion sickness was induced under natural conditions such as air, sea and land transportation. We also included studies in which motion sickness was induced under experimental conditions (analysed separately). Antihistamines were included regardless of class, route or dosage and compared to no treatment, placebo or any other pharmacological or non-pharmacological interventions.. We used standard Cochrane methods. Our primary outcomes were 1) the proportion of susceptible participants who did not experience any motion sickness symptoms; 2) the proportion of susceptible participants who experienced a reduction or resolution of existing symptoms. Secondary outcomes were 1) physiological measures (heart rate, core temperature and gastric tachyarrhythmia (electrogastrography)) and 2) adverse effects (sedation, impaired cognition, blurred vision). We used GRADE to assess the certainty of the evidence for each outcome.. We included nine RCTs (658 participants). Studies were conducted across seven countries, with an overall age range of 16 to 55 years. Motion sickness was induced naturally in six studies and experimentally in four studies (rotating chair). All the naturally induced studies only evaluated first-generation antihistamines (cinnarizine and dimenhydrinate). Risk of bias across the studies varied, with mostly low risk for random sequence generation and allocation concealment, and mostly high risk for selective reporting. Only the experimentally induced studies measured physiological parameters and only the naturally induced studies evaluated adverse effects. There were no studies that clearly assessed the paediatric population. Antihistamines versus placebo or no treatment Antihistamines are probably more effective than placebo at preventing motion sickness symptoms under natural conditions (symptoms prevented: 25% placebo; 40% antihistamines) (risk ratio (RR) 1.81, 95% confidence interval (CI) 1.23 to 2.66; 3 studies; 240 participants) (moderate-certainty). The evidence is very uncertain about the effect of antihistamines on preventing motion sickness under experimental conditions (standardised mean difference (SMD) 0.32, 95% CI -0.18 to 0.83; 2 studies; 62 participants) (very low-certainty). No studies reported results on the resolution of existing motion sickness symptoms. Antihistamines may result in little or no difference in gastric tachyarrhythmia under experimental conditions (mean difference (MD) -2.2, 95% CI -11.71 to 7.31; 1 study; 42 participants) (low-certainty). No studies reported results for any other physiological measures. When compared to placebo, antihistamines may be more likely to cause sedation (sedation: 44% placebo; 66% antihistamines) (RR 1.51, 95% CI 1.12 to 2.02; 2 studies; 190 participants) (low-certainty); they may result in little or no difference in blurred vision (blurred vision: 12.5% placebo; 14% antihistamines) (RR 1.14, 95% CI 0.53 to 2.48; 2 studies; 190 participants) (low-certainty); and they may result in little or no difference in terms of impaired cognition (impaired cognition: 33% placebo; 29% antihistamines) (RR 0.89, 95% CI 0.58 to 1.38; 2 studies; 190 participants) (low-certainty). Antihistamines versus scopolamine The evidence is very uncertain about the effect of antihistamines on preventing motion sickness under natural conditions when compared to scopolamine (symptoms prevented: 81% scopolamine; 71% antihistamin. There is probably a reduction in the risk of developing motion sickness symptoms under naturally occurring conditions of motion when using first-generation antihistamines, in motion sickness-susceptible adults, compared to placebo. Antihistamines may be more likely to cause sedation when compared to placebo. No studies evaluated the treatment of existing motion sickness, and there are few data on the effect of antihistamines in children. The evidence for all other outcomes and comparisons (versus scopolamine, antiemetics and acupuncture) was of low or very low certainty and we are therefore uncertain about these effects of antihistamines.

Topics: Adolescent; Adult; Antiemetics; Child; Cinnarizine; Dimenhydrinate; Histamine Antagonists; Humans; Middle Aged; Motion Sickness; Scopolamine Derivatives; Young Adult

A summary is presented of a programme of work investigating the comparative efficacy of the two drugs most commonly used for seasickness prophylaxis in the Royal Navy, hyoscine and cinnarizine. The programme had both laboratory and sea-trial components. It was shown that hyoscine was a more effective drug than cinnarizine, but cinnarizine had less marked side effects. This comparative superior tolerability of cinnarizine decreased as motion sickness increased. Guidance is given as to the optimum indications for each drug, together with prophylactic regimens.

Topics: Cinnarizine; Humans; Military Personnel; Motion Sickness; Naval Medicine; Randomized Controlled Trials as Topic; Scopolamine

Topics: Animals; Cinnarizine; Clinical Trials as Topic; Double-Blind Method; Guinea Pigs; Humans; Motion Sickness; Piperazines; Rabbits; Vertigo

Flight simulators have an essential role in aircrew training. Occasionally, symptoms of motion sickness, defined as simulator sickness, develop during these sessions. Preventive methods for motion sickness have been investigated thoroughly; however, only a few studies have examined preventive treatments for simulator sickness. The aim of this study was to examine the efficacy of scopolamine (an anticholinergic drug) compared with cinnarizine (an antihistaminic drug) for helicopter simulator sickness prevention. A validated simulator sickness questionnaire (SSQ) score was used to determine the severity of simulator sickness symptoms in this study. Preliminary SSQ scores and SSQ scores after each sortie were calculated. Each participant was given scopolamine, cinnarizine, or a placebo in a double-blind randomized manner before the first sortie of each training day. Forty-one helicopter pilots participated in the trial. The average age was 30.5 ± 7.1 years. SSQ values significantly improved from an average of 73.30 in the preliminary SSQ questionnaire to an average of 30.92 after 2 hours following the administration of cinnarizine (P = .012, 95%CI 8.071-76.703). Scopolamine was found to be less effective than both cinnarizine and the placebo in the alleviation of simulator sickness symptoms. This study is the first to compare scopolamine with cinnarizine for simulator sickness prevention. Based on the results of this study, we recommend the use of cinnarizine over scopolamine for simulator sickness prevention.

Topics: Adult; Cholinergic Antagonists; Cinnarizine; Humans; Motion Sickness; Scopolamine; Surveys and Questionnaires; Young Adult

This study aimed to investigate the clinical and cognitive side effects of baclofen (10 mg), meclizine (25 mg), dimenhydrinate (40 mg) plus cinnarizine (25 mg) and promethazine (25 mg) plus d-amphetamine (10 mg). The study had a double-blind, placebo controlled, repeated measures design and was conducted on healthy male volunteers. The psychomotor vigilance test, the Sternberg working memory task, the implicit memory test and the automated Operation Span (Ospan) task were performed. The Stanford, the Karolinska and the Epworth Sleepiness scale determined the degree of sleepiness. The Profile of Mood States (POMS) evaluated mood states and adverse effects were reported on a 22-item questionnaire. Letter recalls and time for solving mathematical problems, recorded during the Ospan task, were impaired by baclofen and dimenhydrinate-cinnarizine respectively, suggesting an influence of these drugs on the working memory. Significant side effects for baclofen were: sleepiness, tiredness, blurred vision, concentration problems and dizziness whereas for dimenhydrinate-cinnarizine only sleepiness and blurred vision were reported. Meclizine decreased the accuracy on the Sternberg working memory task and thus seemed to affect short-term memory. A reported side effect was increased sleepiness. Promethazine plus d-amphetamine did not affect any of the tested cognitive functions. However, many side effects such as sleepiness, dry mouth, dizziness, vertigo, confusion, insomnia and tremors were reported. The results show that meclizine and dimenhydrinate combined with cinnarizine were the two drugs with the most acceptable combination of side effects.

Topics: Adult; Antiemetics; Baclofen; Cinnarizine; Cognition; Cognition Disorders; Dimenhydrinate; Double-Blind Method; Healthy Volunteers; Humans; Male; Memory; Memory Disorders; Middle Aged; Motion Sickness; Neuropsychological Tests; Promethazine; Psychomotor Performance; Sleep; Sleep Wake Disorders; Surveys and Questionnaires; Young Adult

Pensacola Simulator Sickness Questionnaire (SSQ) is a valuable method to analyse symptoms evoked by exposure to a flight simulator environment that can also be adopted to evaluate the effectiveness of preventive tools, aiming at reducing simulator sickness (SS). In this study we analysed SSQ data in subjects undergoing a standard ground based spatial disorientation training inside a flight simulator, in order to evaluate the SS prevention obtained with two different pharmacological tools. Twelve males volunteers participated to an experimental design based on a double-blind, balanced administration of either 30 mg cinnarizine (CIN), or Cocculus Indicus 6CH (COC), or placebo (PLC) before one trial of about one hour spent inside a spatial disorientation trainer. All subjects underwent the three different conditions (CIN, COC, PLC) during 3 non-consecutive days separated by at least 2 weeks. During each experimental day, all subjects filled in SSQ. In addition, both postural instability (with the use of a static stabilometric platform), and sleepiness symptoms were evaluated. All the tests were performed before and after the simulated flight, at different times, in one-and-half-hour intervals. Results indicated a strong increase of sickness after flight simulation that linearly decreased, showing pre-simulator scores after 1.30 hours. In contrast to both PLC and COC, CIN showed significant side effects immediately following flight simulation, with no benefit at the simultaneous SSQ scores. Globally, no highly significant differences between COC and PLC were observed, although a minor degree of postural instability could be detected after COC administration. As far as the present exposure to a simulator environment is concerned, none of the pharmacological tools administered in this study resulted effective in reducing SS symptoms as detected by the SSQ. Moreover, CIN significantly increased sleepiness and postural instability in most subjects.

Topics: Adult; Antiemetics; Cinnarizine; Cocculus; Cross-Over Studies; Data Interpretation, Statistical; Double-Blind Method; Eye Movements; Humans; Male; Motion Sickness; Plant Extracts; Sleep Stages; Surveys and Questionnaires; Vestibular Function Tests

Our aim was to establish the effects of cinnarizine, a drug used for the treatment of motion sickness, on daytime sleepiness and performance.. The effects of cinnarizine (15, 30, and 45 mg) were assessed on digit symbol substitution, tracking, vigilance, and on subjective and objective (daytime sleep latencies) sleepiness in six healthy volunteers between the ages of 20 and 34 yr (mean 27 yr) from 1.0 h prior to ingestion to 8.0 h after ingestion. The study was placebo-controlled and double-blind in a six-way, cross-over design. Promethazine (10 mg) was used as an active control.. No effects of 15 mg cinnarizine were observed on performance. Sleep latencies were reduced at 3.5 and 5.0 h after ingestion, and the subjects as a group reported increased sleepiness at 5.0 and 6.5 h after ingestion. With 30 mg cinnarizine there was evidence of impaired performance at 5.0, 6.5, and 8.0 h after ingestion. Sleep latencies were not reduced, but the subjects as a group reported increased sleepiness 5.0 h after ingestion. With 45 mg cinnarizine there was evidence of impaired performance 5.0 h after ingestion. Sleep latencies were reduced at 5.0 and 6.5 h after ingestion, and the subjects as a group reported increased sleepiness 6.5 h after ingestion. Promethazine (10 mg) shortened sleep latencies from 2.5 to 5.0 h after ingestion, and the subjects as a group reported increased sleepiness overthis period.. Cinnarizine is not free of central activity over the usual therapeutic dose range of 15 to 30 mg. It is contraindicated for motion sickness in aircrew involved in the control of aircraft. Caution should be exercised in the use of the drug by other aircrew who may be involved in tasks which demand continued attention.

Topics: Adult; Aerospace Medicine; Cinnarizine; Cross-Over Studies; Double-Blind Method; Female; Histamine H1 Antagonists; Humans; Male; Motion Sickness; Promethazine; Psychomotor Performance; Sleep

We assessed the influence of dimenhydrinate, cinnarizine and transdermal scopolamine on the ability to perform simulated naval crew tasks. The effect of single doses of dimenhydrinate, 100 mg, cinnarizine, 50 mg, and one transdermal scopolamine patch on psychomotor performance was evaluated using a double-blind, placebo-controlled, randomized, crossover design in three separate studies. A total of 60 young naval crew (20 for dimenhydrinate, 15 for cinnarizine and 25 for transdermal scopolamine) underwent a battery of computerized and paper and pencil performance tests, and filled out a questionnaire on side-effects and well-being self-assessment. Dimenhydrinate significantly impaired decision reaction time and auditory digit span. Most of the subjects who took dimenhydrinate also reported a subjective decrease in well-being and general performance abilities. Cinnarizine and transdermal scopolamine did not affect performance abilities. Cinnarizine was free of significant side-effects. Dry mouth was the only significant side-effect of transdermal scopolamine. These findings could be explained by the well-known sedative properties of dimenhydrinate and not by a specific effect on any particular cognitive or motor function. Our results suggest that dimenhydrinate, 100 mg, adversely affects psychomotor function, whereas single doses of cinnarizine, 50 mg, and transdermal scopolamine appear to be free of side-effects on performance and seem to be a preferable anti-seasickness drug for use by a naval crew.

Topics: Administration, Cutaneous; Administration, Oral; Adolescent; Adult; Arousal; Attention; Cinnarizine; Cross-Over Studies; Dimenhydrinate; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Humans; Male; Mental Recall; Military Personnel; Motion Sickness; Neuropsychological Tests; Psychomotor Performance; Scopolamine

Scopolamine was compared with cinnarizine in a double-blind sea trial involving 179 subjects from the crews of 2 warships. Medication was initiated prophylactically when weather information indicated the approach of nauseogenic conditions. Ship motion was measured during drug treatment periods. In one ship, moderate to severe nauseogenic conditions were encountered; a parallel group comparison was achieved in this. In the other ship, the motion experienced was of a mild nature; a crossover comparison was achieved. Scopolamine was shown to be more effective than cinnarizine in protecting against the symptoms of seasickness. In mild motion, cinnarizine was better tolerated than scopolamine in having less marked side effects. As motion severity increased, the comparative tolerability of scopolamine improved.

Topics: Cinnarizine; Cross-Over Studies; Double-Blind Method; Humans; Military Personnel; Motion Sickness; Naval Medicine; Scopolamine

In a double-blind, placebo-controlled study, we evaluated the effect of two different doses of cinnarizine in the prevention of seasickness in very rough seas. We divided 95 healthy male subjects into 3 groups which received: cinnarizine 50 mg, cinnarizine 25 mg, and placebo. Seasickness susceptibility and severity were evaluated by a standard questionnaire concerning the subject's condition on previous voyages (seasickness susceptibility), and the subject's condition immediately after a 4-6-h voyage in very rough seas with 3.5 m waves (seasickness severity). Possible side effects of the drug were also evaluated by filling in a further questionnaire. Of the 31 subjects who received cinnarizine 50 mg, 65% felt better during the present voyage than on previous voyages, compared to 41% of the 32 subjects who received cinnarizine 25 mg and 31% of the 32 who received placebo. A significant difference (p < 0.05) was found between the cinnarizine 50 mg and placebo groups, while cinnarizine 25 mg was no more effective than placebo. No notable side effects were found for any drug group. In conclusion, cinnarizine 50 mg was found to be effective in the prevention of seasickness in rough seas.

Topics: Adolescent; Adult; Cinnarizine; Double-Blind Method; Humans; Male; Motion Sickness; Naval Medicine

Cinnarizine was evaluated for the prevention of seasickness in a laboratory and sea study. The effects of 25 mg cinnarizine on the vestibulo-ocular reflex were investigated in 13 subjects. Significant reduction of the gain in response to sinusoidal oscillations at 0.02, 0.08, and 0.16 Hz (p < 0.05) and increased phase lead at 0.16 Hz (p < 0.01) were observed. The effect of 25 and 50 mg cinnarizine on seasickness severity was examined in 95 subjects during a voyage in rough seas. Seasickness symptoms were improved in 69% of the subjects by 50 mg cinnarizine versus 35% and 31% in the groups receiving 25 mg cinnarizine and placebo (p < 0.05 and p < 0.01, respectively). The percentage of vomiting protection provided by 50 mg cinnarizine was 63% (p < 0.05). We conclude that 50 mg cinnarizine is an effective drug for the prevention of seasickness. The reduction in vestibular sensitivity observed even after administration of 25 mg cinnarizine may explain the potency of cinnarizine in the prevention of seasickness.

Topics: Adolescent; Adult; Cinnarizine; Double-Blind Method; Humans; Male; Motion Sickness; Reflex, Vestibulo-Ocular; Severity of Illness Index; Vomiting

Four test medications were randomly examined in 25 volunteers for the depressant effect on the labyrinth during stimulation in a rotation chair as well as in a parallel swing. The medications, placebo (pl), Domperidone 30 mg (D), Cinnarizine 40 mg (C) and Touristil 40 mg + 30 mg (C+D), were tested at 1-week intervals, the duration and amplitude of nystagmus having been recorded 15 min, 30 min, 1, 2, 3 and 4 h after intake of the medication. In both tests Touristil (C+D) was significantly (p less than 0.01) to very significantly (p less than 0.0001) more potent, more rapid, and longer working than placebo and the separate components (C) and (D). In addition the working of Touristil was specifically superior to Cinnarizine, when given separately. It appears that the new preparation Touristil approaches the profile of the ideal drug against motion sickness more closely than any other medication.

Topics: Administration, Oral; Adult; Cinnarizine; Domperidone; Double-Blind Method; Drug Combinations; Female; Humans; Male; Motion Sickness; Nystagmus, Physiologic; Random Allocation; Vestibule, Labyrinth

Flunarizine is a calcium antagonist which has proved clinically useful in controlling chronic vertigo. In a double blind crossover trial 10 subjects were used to compare the electronystagmic responses to motion in patients taking flunarizine, prochlorperazine maleate, or placebo. Flunarizine is shown to be a powerful peripherally acting labyrinthine suppressant, with application in the prevention of motion sickness. Flunarizine produces none of the central depressive side effects characteristic of antihistamines and anticholinergics, which are the conventional anti-motion sickness drugs.

Topics: Adult; Calcium Channel Blockers; Cinnarizine; Clinical Trials as Topic; Double-Blind Method; Electronystagmography; Flunarizine; Humans; Male; Motion Sickness; Prochlorperazine; Vertigo

The investigations on the therapeutic effect of cinnarizine in 112 passengers of a ship complaining of seasickness was carried out. In 5 cases no improvement was found, and 7 results were questionable. The results obtained in the group cured with cinnarizine compared with those in the group where Aviomarin and placebo were administered show great efficacy of cinnarizine. It seems that the therapy with this medicine could be recommended.

Topics: Adult; Cinnarizine; Dimenhydrinate; Female; Humans; Male; Motion Sickness; Piperazines

Topics: Cinnarizine; Clinical Trials as Topic; Follow-Up Studies; Humans; Motion Sickness; Piperazines; Random Allocation; Scopolamine

Topics: Adolescent; Adult; Aged; Cinnarizine; Clinical Trials as Topic; Double-Blind Method; Humans; Middle Aged; Motion Sickness; Piperazines; Placebos; Random Allocation

Topics: Animals; Cinnarizine; Clinical Trials as Topic; Double-Blind Method; Guinea Pigs; Humans; Motion Sickness; Piperazines; Rabbits; Vertigo

Topics: Calcium; Calcium Channels, L-Type; Cinnarizine; Humans; Motion Sickness

Sea sickness may greatly impact the readiness of Service personnel deployed aboard naval vessels. Medications used in the treatment of sea sickness may have adverse effects, limiting their use as flight crew. Although the prevalence of sea sickness in flight crews remains unclear, individual susceptibility and high sea states are established risk factors. Literature review can guide optimized management strategies for this population.. The first author conducted a PubMed search using the terms "sea sickness" "flight crew" "scopolamine," "hyoscine," and "cinnarizine," identifying 15 articles of 350 matches, which addressed potential impact to flight performance. Analysis also included two historic reports about motion sickness maintained within the U.K. Army Aviation Centre's aeromedical archives in Middle Wallop, Hampshire. Both authors reviewed aeromedical policy for the International Civil Aviation Organization, U.K. Civil Aviation Authority, U.S. Federal Aviation Authority, the National Aeronautics Space Administration, U.S. Army, U.S. Navy, and U.S. Air Force.. Scopolamine, also known as hyoscine, has fewer operationally relevant side effects than cinnarizine or first-generation antihistamines. Although no aeromedical authorities endorse the unsupervised use of scopolamine, many will consider authorizing its temporary use following an initial assessment on the ground. Evidence supports the concomitant use of stimulant medication for augmenting antinausea effects and countering the potential sedative effects of scopolamine.. Scopolamine should be considered as a first-line medication for flight crews at risk of sea sickness but such use must be guided by the appropriate aeromedical authority, ideally in conjunction with a ground trial to evaluate individual response. The limited evidence to support concurrent use of stimulants must be weighed against the challenges of maintaining accountability of controlled substances in the operational environment.

Topics: Aerospace Medicine; Cinnarizine; Disease Management; Histamine Antagonists; Humans; Military Personnel; Motion Sickness; Pilots; Risk Factors; Scopolamine

Motion sickness can be a limiting factor for sea and air missions. We report the experience of a Pararescue (PJ) team on a Pacific Ocean rescue mission in which motion sickness was prevalent. Cinnarizine, an antagonist of H1-histamine receptors, was used to treat affected PJs. We also report findings of a survey of PJs regarding motion sickness. A family of four on a disabled sailboat 900 miles off the coast of Mexico sent out a distress call because their 1-year-old daughter became severely ill with fever and diarrhea. Four PJs were deployed on a C-130, performed a free-fall parachute insertion into the ocean, and boarded the sailboat. All four PJs experienced onset of motion sickness at some point during the early part of the mission and symptoms persisted through the first 24 hours. Three PJs experienced ongoing nausea, vomiting, dizziness, and sensory imbalances. The captain of the sailboat offered the three sick PJs approximately 18mg of cinnarizine two or three times a day with relief of symptoms and improvement on operational effectiveness. A new, anonymous, voluntary survey of Air National Guard PJs and combat rescue officers revealed that 78.4% of Operators have experienced motion sickness at sea. We discuss the current theories on motion sickness, the effect of motion sickness on operational effectiveness, and research on treatment of motion sickness, including the medication cinnarizine.

Topics: Aircraft; Cinnarizine; Emergency Responders; Histamine H1 Antagonists; Humans; Male; Military Medicine; Motion Sickness; Ships

Severe seasickness could pose a serious problem in diving, and anti-seasickness medication should therefore be prescribed for the seasickness-susceptible diver. Cinnarizine may be used as a medication if it does not increase the risk of central nervous system (CNS) oxygen toxicity when diving with closed-circuit oxygen or O2-enriched gas mixtures. Twenty-six male, white Sprague-Dawley rats were exposed to high O2 pressures (507 and 608 kPa) before and after cinnarizine ingestion (3.3 mg.kg-1), until the appearance of the first electrical discharge (FED) in the electroencephalogram (EEG) which precedes the clinical convulsions. Each rat was tested on five exposure protocols (control and cinnarizine at 507 kPa O2, control, cinnarizine, and 15 h starvation as a control for cinnarizine at 608 kPa O2) at intervals of at least 2 days or until the EEG connector became detached (a mean of 3.1 exposures per rat). Latency to the FED increased after cinnarizine ingestion in 16 of the 17 pairs of measurements at 507 kPa O2 (by more than 61%, P < 0.002) and in 17 of the 19 pairs of measurements at 608 kPa O2 (by 36%, P < 0.002). There was no significant effect of 15 h starvation. Cinnarizine can be further considered for use in seasickness-susceptible divers as it does not increase the risk of CNS O2 toxicity.

Topics: Animals; Antiemetics; Brain; Cinnarizine; Diving; Electroencephalography; Food Deprivation; Histamine H1 Antagonists; Male; Motion Sickness; Oxygen; Rats; Rats, Sprague-Dawley

To study the mechanism of cinnarizine in preventing motion sickness, TXB2, 6-Keto-PGF1 alpha in rats' blood plasma and Na(+)-K(+)-ATPase activity in the endothelial cells of their cerebellar capillary were measured and analysed by a radioactive immunity analyser and a computer image system. The results showed that TXB2 and 6-Keto-PGF1 alpha in rats' blood plasma in the cinnarizine preventing group (CPG) decreased remarkably, compared with those in the motion sickness group(MSG) (p < 0.05). The activity of Na(+)-K(+)-ATPase in the endothelial cells of rats' cerebellar capillary in CPG was higher than that in MSG (p < 0.01). The authors suggest that the lower concentration of TXB2 and 6-Keto-PGF1 alpha in rats' blood plasma in CPG is closely related to cinnarizine which prevents Ca2+ from entering into the platelets and into the endothelial cells of blood vessels. The higher activity of Na(+)-K(+)-ATPase in the cerebellum may be caused by cinnarizene which dilates the blood vessels in the brain, increases the blood flow therein, and hinders Ca2+ from getting into the cerebellum cells. These change are believed to be the important mechanism of how cinnarizine prevents motion sickness.

Topics: Animals; Cerebellum; Cinnarizine; Female; Image Processing, Computer-Assisted; Male; Motion Sickness; Prostaglandins; Rats; Rats, Sprague-Dawley; Sodium-Potassium-Exchanging ATPase

Topics: Aerospace Medicine; Cinnarizine; Humans; Motion Sickness; Scopolamine

Topics: Basal Ganglia Diseases; Cinnarizine; Female; Humans; Middle Aged; Motion Sickness

Space motion sickness (SMS) has been a perplexing problem in both the Soviet and U.S. manned space programs. Both the sensory conflict theory (neuronal signal mismatch) and the cephalad fluid shift concept explain the mechanism. This paper reviews the mechanism of action of various drugs that primarily affect brain blood flow or brain metabolism. In particular, Cavinton (apovincamic acid ethyl ester) has been used successfully in offsetting SMS in experimental test subjects.

Topics: Adolescent; Adult; Aerospace Medicine; Cinnarizine; Coriolis Force; Electrocardiography; Humans; Hungary; Male; Motion Sickness; Posture; Scopolamine; USSR; Vinca Alkaloids

An open study was carried out in 79 children known to be susceptible to car sickness to assess the efficacy and tolerance of cinnarizine used prophylactically. Each child received one 15 mg cinnarizine tablet 2 hours before a long car journey and a further half-tablet every 8 hours thereafter, if required. The results of the children's assessments indicated that 81% considered the preparation either 'good' or 'excellent' and 69% of the 68 who had previously received other medication for travel sickness rated it 'better' or 'much better'. Only 4% of the children vomited and only 14% felt sleepy or drowsy. All but 3 of the 52 doctors who participated were prepared to give cinnarizine again to their charges based on the experience of this study.

Topics: Child; Child, Preschool; Cinnarizine; Female; Humans; Male; Motion Sickness; Piperazines